<DOC>
	<DOC>NCT00362765</DOC>
	<brief_summary>Double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.Patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate combination.</brief_summary>
	<brief_title>Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus and dyslipidemia. Type 1 diabetes.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Hyperinsulinemic</keyword>
	<keyword>Clamp</keyword>
	<keyword>Metformin</keyword>
	<keyword>Fenofibrate</keyword>
</DOC>